Clinical trials: sponsored by Amgen
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma Lipoprotein(a) [Lp(a)].
- Trial name
- NCT03626662
- Testing
- AMG 890
- Where
- 9 sites in United States, Australia
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Amgen
Atopic Dermatitis
A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants
The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants.
- Trial name
- NCT06438263
- Testing
- Rocatinlimab
- Where
- 3 sites in United States
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Amgen
Obesity
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
The main objective of the study is to assess the pharmacokinetics (PK) of Maridebart Cafraglutide after a single subcutaneous (SC) administration in overweight or obese Chinese participants.
- Trial name
- NCT06352892
- Testing
- Maridebart Cafraglutide
- Where
- Hong Kong
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Amgen
Atopic Dermatitis
A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants
The primary objective of the study is to evaluate the pharmacokinetics of rocatinlimab after single subcutaneous (SC) administration in healthy Chinese participants.
- Trial name
- NCT06214481
- Testing
- Rocatinlimab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Amgen
Migraine
Aimovig Pregnancy Exposure Registry
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed…
- Trial name
- NCT06150781
- Testing
- erenumab-aooe
- Where
- United States
- Volunteers
- 2,842 people, healthy volunteers welcome
- Sponsor
- Amgen
Obesity
Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity
The primary objective of this study is to assess the safety and tolerability of AMG 786 as single or multiple doses in healthy and obese participants.
- Trial name
- NCT05406115
- Testing
- AMG 786
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants
The primary objective of the study is to evaluate the PK of digoxin administered alone and in combination with AMG 510 in healthy participants.
- Trial name
- NCT05598281
- Testing
- AMG 510, Digoxin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
The primary objective of this study is to evaluate the PK profile of AMG 510 alone and in combination with omeprazole in healthy participants.
- Trial name
- NCT05581992
- Testing
- AMG 510, Omeprazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of AMG 510 alone and in combination with rifampin in healthy participants.
- Trial name
- NCT05577624
- Testing
- AMG 510, Rifampin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Volunteers
Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants
The primary objectives of this study are to evaluate the effect of AMG 510 on the pharmacokinetics (PK) of metformin in healthy participants and to evaluate the effect of metformin on the PK of AMG 510 in healthy participants.
- Trial name
- NCT05550129
- Testing
- AMG 510, Metformin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
The primary objective of the study is to evaluate the PK of AMG 510 administered in the fasted and fed state in healthy participants.
- Trial name
- NCT05581758
- Testing
- AMG 510
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
The primary objective of the study is to evaluate the pharmacokinetic (PK) profile of AMG 510 administered alone and in combination with itraconazole in healthy participants.
- Trial name
- NCT05568082
- Testing
- AMG 510, Itraconazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
The primary objective of this study is to evaluate the pharmacokinetics (PK) of AMG 133 after single subcutaneous (SC) administration in healthy Japanese and Caucasian participants.
- Trial name
- NCT05056246
- Testing
- AMG 133
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Amgen
Obesity
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research…
- Trial name
- COSMOS-DIGITAL (NCT06761703)
- Testing
- TAP® Micro Select Device (Touch Activated Phlebotomy)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amgen
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism
This trial will evaluate if fomepizole (4-methylpyrazole) can treat symptoms associated with alcohol intolerance due to aldehyde dehydrogenase 2 (ALDH2) deficiency, an inherited metabolic disorder.
- Trial name
- NCT00661141
- Testing
- Antizol, Ethanol
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
Safety Issues
A Phase1 Study of VIB9600
Overall design: Single-center, randomized, blinded, placebo-controlled single- and multiple-ascending dose study in healthy adult subjects.
- Trial name
- NCT03621605
- Testing
- VIB9600
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
The primary objective of this study is to evaluate the PK of AMG 510 alone and in combination with either famotidine or omeprazole in healthy participants under fed conditions.
- Trial name
- NCT05599828
- Testing
- AMG 510, Omeprazole, Famotidine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Volunteers
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and…
- Trial name
- NCT06674941
- Testing
- Teprotumumab
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
Bioavailability, Bioequivalence
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
The primary objective of this study is to assess the pharmacokinetics (PK) parameters of a single subcutaneous (SubQ) infusion of TEPEZZA with and without ENHANZE™ Drug Product (EDP) at 2 dose levels in healthy adult participants.
- Trial name
- NCT06563856
- Testing
- TEPEZZA, EDP
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy
A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)
To determine the safety and tolerability of single oral doses of HPN-100 as a formulation (GT4P-F) and GT4P as the active pharmaceutical ingredient (GT4P-API) administered to healthy male subjects.
- Trial name
- NCT00977600
- Testing
- HPN-100, Ammonul, Buphenyl
- Where
- Ukraine
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amgen